Australia - English - Department of Health (Therapeutic Goods Administration)

results sales promotion t/a true collection - 4-methylbenzylidene camphor,bemotrizinol,butyl methoxydibenzoylmethane,octocrylene -

Australia - English - Department of Health (Therapeutic Goods Administration)

results laser clinic pty ltd - butyl methoxydibenzoylmethane,octocrylene,oxybenzone,phenylbenzimidazole sulfonic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

results laser clinic pty ltd - butyl methoxydibenzoylmethane, quantity: 25 mg/g; oxybenzone, quantity: 30 mg/g; octocrylene, quantity: 70 mg/g; phenylbenzimidazole sulfonic acid, quantity: 20 mg/g - cream - excipient ingredients: phenoxyethanol; iodopropynyl butylcarbamate; ethylhexylglycerin; purified water; disodium edetate; dl-alpha-tocopheryl acetate; carbomer u-10; potassium cetyl phosphate; cetostearyl alcohol; alkyl (c12-15) benzoate; sodium hydroxide; glyceryl monostearate; sorbitan stearate; glycerol - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

United States - English - NLM (National Library of Medicine)

hb media llc (dba optimal results) - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antibacterial for rinse-free hand sanitizing to remove 99.9% bacteria on skin.

United States - English - NLM (National Library of Medicine)

results rna, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - acne treatment for the treatment of acne step 1: remove one moistened pad from the main jar and place pad inside jar lid. step 2: to activate pad, moisten pad further with 10 sprays of activator solution. step 3: using activated pad, cover affected skin areas with wiping motion. repeat until pad moisture is used. step 4: allow formula to fry and remain on skin. do not rinse off. results rna www.nexiclear.com orem, utah 84058 made in usa patent pending satisfaction guaranteed 1 888 823 3869

United States - English - NLM (National Library of Medicine)

results rna, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - acne treatment for the treatment of acne step 1: remove one moistened pad from the main jar and place pad inside jar lid. step 2: to activate pad, moisten pad further with 10 sprays of activator solution. step 3: using activated pad, cover affected skin areas with wiping motion. repeat until pad moisture is used. step 4: allow formula to fry and remain on skin. do not rinse off. results rna www.complexion clear.com orem, utah 84058 made in usa patent pending satisfaction guaranteed 1 888 823 3869

New Zealand - English - Ministry for Primary Industries

sprayshop limited - 2,4-d - 2,4-d 625 g/litre - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefepime hydrochloride monohydrate, quantity: 595 mg (equivalent: cefepime, qty 500 mg) - injection, powder for - excipient ingredients: arginine - adults: cefepime-aft is indicated in the treatment of the infections listed below when caused by susceptible bacteria. ? lower respiratory tract infections, including pneumonia and bronchitis. ? urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. ? skin and skin structure infections. ? intra-abdominal infections, including peritonitis and biliary tract infections. ? gynaecological infections. ? septicaemia ? empiric treatment in febrile neutropenic patients (see precautions) cefepime-aft is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered. paediatrics: cefepime-aft is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria: ? pneumonia ? urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections ? skin and skin structure infections ? septicaemia ? empiric treatment in febrile neutropenic patients (see precautions) culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empiric therapy with cefepime-aft may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, cefepime-aft can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime-aft. in patients who are at risk of mixed aerobic-anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefepime hydrochloride monohydrate, quantity: 2.378 g (equivalent: cefepime, qty 2 g) - injection, powder for - excipient ingredients: arginine - adults: cefepime-aft is indicated in the treatment of the infections listed below when caused by susceptible bacteria. ? lower respiratory tract infections, including pneumonia and bronchitis. ? urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. ? skin and skin structure infections. ? intra-abdominal infections, including peritonitis and biliary tract infections. ? gynaecological infections. ? septicaemia ? empiric treatment in febrile neutropenic patients (see precautions) cefepime-aft is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered. paediatrics: cefepime-aft is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria: ? pneumonia ? urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections ? skin and skin structure infections ? septicaemia ? empiric treatment in febrile neutropenic patients (see precautions) culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empiric therapy with cefepime-aft may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, cefepime-aft can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime-aft. in patients who are at risk of mixed aerobic-anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefepime hydrochloride monohydrate, quantity: 1.189 g (equivalent: cefepime, qty 1 g) - injection, powder for - excipient ingredients: arginine - adults: cefepime-aft is indicated in the treatment of the infections listed below when caused by susceptible bacteria. ? lower respiratory tract infections, including pneumonia and bronchitis. ? urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. ? skin and skin structure infections. ? intra-abdominal infections, including peritonitis and biliary tract infections. ? gynaecological infections. ? septicaemia ? empiric treatment in febrile neutropenic patients (see precautions) cefepime-aft is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered. paediatrics: cefepime-aft is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria: ? pneumonia ? urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections ? skin and skin structure infections ? septicaemia ? empiric treatment in febrile neutropenic patients (see precautions) culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empiric therapy with cefepime-aft may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, cefepime-aft can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime-aft. in patients who are at risk of mixed aerobic-anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.